Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaogeng Wang

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of Cancer|July 16, 2019
P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertibWenlong Li, Matthijs Tibben, Yaogeng Wang, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)Yaogeng Wang, Rolf W Sparidans, Sander Potters, et al.
International Journal of Pharmaceutics|November 24, 2019
P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554)Wenlong Li, Rolf Sparidans, Mujtaba El-Lari, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 24, 2021
Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinibYaogeng Wang, Rolf W Sparidans, Jing Wang, et al.
International Journal of Cancer|May 11, 2018
P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinibWenlong Li, Rolf W Sparidans, Yaogeng Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 16, 2023
Pharmacokinetics of the KRAS<sup>G12C</sup> inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1cNancy H C Loos, Irene A Retmana, Jamie Rijmers, et al.
Pharmacological Research|March 12, 2023
Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugsWenlong Li, Dilek Iusuf, Rolf W Sparidans, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 1, 2024
Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugsWenlong Li, Rolf W Sparidans, Yaogeng Wang, et al.
Acta Pharmaceutica Sinica. B|March 6, 2023
Carboxylesterase 1 family knockout alters drug disposition and lipid metabolismChangpei Gan, Jing Wang, Alejandra Martínez-Chávez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 2, 2023
Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome developmentChangpei Gan, Jing Wang, Yaogeng Wang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of Cancer|July 16, 2019
P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertibWenlong Li, Matthijs Tibben, Yaogeng Wang, et al.
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)Yaogeng Wang, Rolf W Sparidans, Sander Potters, et al.
International Journal of Pharmaceutics|November 24, 2019
P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554)Wenlong Li, Rolf Sparidans, Mujtaba El-Lari, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|December 24, 2021
Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinibYaogeng Wang, Rolf W Sparidans, Jing Wang, et al.
International Journal of Cancer|May 11, 2018
P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinibWenlong Li, Rolf W Sparidans, Yaogeng Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 16, 2023
Pharmacokinetics of the KRAS<sup>G12C</sup> inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1cNancy H C Loos, Irene A Retmana, Jamie Rijmers, et al.
Pharmacological Research|March 12, 2023
Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugsWenlong Li, Dilek Iusuf, Rolf W Sparidans, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 1, 2024
Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugsWenlong Li, Rolf W Sparidans, Yaogeng Wang, et al.
Acta Pharmaceutica Sinica. B|March 6, 2023
Carboxylesterase 1 family knockout alters drug disposition and lipid metabolismChangpei Gan, Jing Wang, Alejandra Martínez-Chávez, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 2, 2023
Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome developmentChangpei Gan, Jing Wang, Yaogeng Wang, et al.
Pageof 2